A Newly Initiated Phase 1 Study Will Evaluate AIV007 for Wet AMD, DME 
Skitterphoto / Pixabay

A Newly Initiated Phase 1 Study Will Evaluate AIV007 for Wet AMD, DME 

  In late May 2023, clinical-stage biotechnology company AiViva Biopharma Inc. ("AiViva") shared via news release that the company had launched a Phase 1 clinical study evaluating AIV007 for diabetic…

Continue Reading A Newly Initiated Phase 1 Study Will Evaluate AIV007 for Wet AMD, DME